A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial).

Trial Profile

A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Everolimus (Primary) ; Ganitumab (Primary) ; Panitumumab (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms RAP
  • Most Recent Events

    • 09 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
    • 09 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 05 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top